The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
复制标题

TNFRS OX40、4-1BB和CD40作为癌症免疫疗法的靶标。

DOI:
10.1016/j.coi.2013.01.004
复制
发表时间:
2013-04
影响因子:
7
通讯作者:
Weinberg AD
Weinberg AD
中科院分区:
医学2区
文献类型:
--
作者:
Moran AE;Kovacsovics-Bankowski M;Weinberg AD

文献摘要

参考文献

被引文献

相似文献

T细胞介导的肿瘤排斥需要来自T细胞受体和共刺激分子的信号以许可肿瘤抗原特异性T细胞的效应子功能。在肿瘤微环境中还有一系列免疫抑制机制,可以抑制抗肿瘤免疫。使用单克隆抗体克服这种抑制和/或增强肿瘤抗原特异性T细胞应答在临床试验中显示出希望。特别地,用激动剂Ab靶向肿瘤坏死因子受体(TNFR)家族的共刺激成员增强了T细胞功能,这已经导致在携带癌症的宿主中的令人鼓舞的治疗结果。这些令人鼓舞的数据建立肿瘤坏死因子受体作为增强肿瘤特异性免疫反应在小鼠和man. This审查的重要目标将集中在激动剂,靶向肿瘤坏死因子受体OX 40,4-1BB,和CD 40。
T cell-mediated rejection of tumors requires signals from the T cell receptor and co-stimulatory molecules to license effector functions of tumor-antigen specific T cells. There is also an array of immune suppressive mechanisms within the tumor microenvironment that can suppress anti-tumor immunity. The use of monoclonal antibodies to overcome this suppression and/or enhance tumor-antigen specific T cell responses has shown promise in clinical trials. In particular, targeting co-stimulatory members of the tumor necrosis factor receptor (TNFR) family with agonist Abs enhances T cell function, which has led to encouraging therapeutic results in cancer-bearing hosts. These encouraging data establish TNFRs as important targets for enhancing tumor-specific immune responses in mice and man. This review will focus on agonists that target the TNFRs OX40, 4-1BB, and CD40.
DOI: 10.1056/nejmoa1003466
发表时间: 2010-08-19
期刊: The New England journal of medicine
影响因子: --
作者:
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者: Urba WJ
鉴定人OX-40配体,这是具有与肿瘤坏死因子同源的CD4+ T细胞的costimulator。
DOI: 10.1084/jem.180.2.757
发表时间: 1994-08-01
影响因子: 15.3
作者:
Godfrey, Wayne R.;Fagnoni, Francesco F.;Haraa, Marwan A.;Buck, David;Engleman, Edgar G.
通讯作者: Engleman, Edgar G.
DOI: 10.1084/jem.20082205
发表时间: 2009-05-11
期刊: The Journal of experimental medicine
影响因子: --
作者:
Hirschhorn-Cymerman D;Rizzuto GA;Merghoub T;Cohen AD;Avogadri F;Lesokhin AM;Weinberg AD;Wolchok JD;Houghton AN
通讯作者: Houghton AN
DOI: 10.1097/cji.0b013e318209e7ec
发表时间: 2011-04
期刊: Journal of immunotherapy (Hagerstown, Md. : 1997)
影响因子: --
作者:
Hernandez-Chacon JA;Li Y;Wu RC;Bernatchez C;Wang Y;Weber JS;Hwu P;Radvanyi LG
通讯作者: Radvanyi LG
DOI: 10.1111/j.1365-2141.2012.09251.x
发表时间: 2012-10-01
影响因子: 6.5
作者:
Bensinger, William;Maziarz, Richard T.;Stadtmauer, Edward A.
通讯作者: Stadtmauer, Edward A.